Oct 5, 2022 • 57M

Ep. 23 - Drugs

The FLATLINING Podcast

 
0:00
-57:09
Open in playerListen on);
The FLATLINING Podcast brings you great healthcare analysis and discussion each week from industry experts who know their way around politics, economics, and a doctors office. Subscribe for more great content and check out the articles at www.FLATLINING.net.
Episode details
Comments

This week, Ron and Matthew discuss new results from the Kaiser Family Foundation’s COVID-19 Vaccine Monitor. This time, some people aren’t sure about booster shots.

Then they discuss why the FDA is approving drugs like Aduhelm and Relyvrio. These new drugs are very expensive but not very effective. What is the point of approving drugs that don’t do much?

  • Where can I find more information on the COVID-19 booster shots?

  • How many people have been boosted for COVID-19?

  • Why are drugs so expensive?

  • Why won’t Medicare cover Aduhelm?

  • Should the definition of “medicine” and “healthcare” be expanded?

  • Should IVF and other fertility measures be covered by employer healthcare?

  • Why are there limited drugs for superbugs?

Share

Let us know what you think in the comments below, email us at flatlining@substack.com, or tweet Matthew or Ron.

Subscribe to the FLATLINING Podcast on Apple PodcastsSpotify, the iHeartRadio appAmazon MusicGoogle Podcasts, and Audible.

Follow Matthew (@radioHandley) and Ron (@RonHowrigon) on Twitter.


Articles mentioned in this program:

KFF COVID-19 Vaccine Monitor: September 2022 - Kaiser Family Foundation

Cost and Risk - Ron Howrigon in FLATLINING.net

Sandbagging an Alzheimer’s Treatment - The Editorial Board of The Wall Street Journal

ALS drug wins FDA approval despite questionable data - ABC News

IRA’s Drug Price ‘Negotiation’ Provisions Are the Wrong Answer to the Right Question - Mei Mei Hu in RealClear Health

Why We Will Never Control Medical Costs - Wesley J. Smith in National Review

The war against superbugs caught in congressional quagmire - POLITICO